At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 30 enrolled
Drug / intervention
Durvalumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy.
In Brief
A Phase 3 clinical trial evaluating Durvalumab and Placebo for Carcinoma, Non- Small Cell Lung. Completed, enrolled 30 participants across 115 sites in 25 countries.
Detailed Summary
This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non- Small Cell Lung
CountriesArgentina, Australia, Belgium, Brazil, Canada, Czechia, France, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Netherlands, Peru, Poland, Russia, Singapore, South Korea, Spain, Taiwan, Turkey (Türkiye), United States, Vietnam
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartNov 2020
Primary CompletionMay 2023
Study CompletionJan 2024
TodayJul 2026
First PostedNov 24, 2020
Enrollment StartNov 30, 2020
Primary CompletionMay 31, 2023
Study CompletionJan 15, 2024
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 5.6 years ago
Interventions
Durvalumabdrug
Intravenous administration of Durvalumab
Placeboother
Placebo Comparator